TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05366621
Drug: Anti-osteoporosis medications
Normalized name: pramoxine hydrochloride Medicated Pad [Scalpicin Anti-Itch]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication exposure was defined as the usage of osteoporosis medications approved by the Taiwan Food and Drug Administration (TFDA), including alendronate, risedronate, ibandronate, zoledronic acid, denosumab, raloxifene, bazedoxifene, calcitonin, and teriparatide, but excluded patients using the osteoporosis medication for cancer-related treatments (such as high dosing frequency of zoledronic acid or denosumab).
Study: NCT00614445
Drug: doxylamine succinate 10 mg/pyridoxine hydrochloride 10 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: up to 4 tablets daily, titrated according to the protocol
Study: NCT00614445
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 to 4 tablets daily titrated according to the protocol
Study: NCT01812213
Drug: [18F]NAV4694
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT05378711
Drug: Fluoxetine
Normalized name: Fluoxetine
DrugBank: Fluoxetine (DB00472)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Children will receive a placebo or fluoxetine at different times dependent upon random assignment to a treatment schedule.
Study: NCT03263910
Drug: NPO-11
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 ml NPO-11
Study: NCT03263910
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 ml NPO-11(Placebo)
Study: NCT02817789
Drug: Combination lysine acetylsalicylate - clopidogrel
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75 mg before and 75 mg daily after the procedure of lysine acetylsalicylate and 300mg loading dose before and 75 mg of clopidogrel daily after the procedure
Study: NCT03319459
Drug: FATE-NK100
Approvals — FDA: no, EMA: no, PMDA: no
Description: FATE-NK100 is a donor-derived NK cell product comprised of ex vivo activated effector cells with enhanced anti-tumor activity
Study: NCT04444986
Drug: AVIGAN 200 mg FT
Approvals — FDA: no, EMA: no, PMDA: no
Description: AVIGAN containing 200 mg favipiravir manufactured by Toyama, Japan
Study: NCT04094493
Drug: vit D
Normalized name: Tri-Vit Drops
Approvals — FDA: no, EMA: no, PMDA: no
Description: preoperative intra muscular vit D injection
Study: NCT02414945
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01111383
Drug: tobramycin
Normalized name: Tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 300mg/4ml solution, via a nebuliser, over a 48-week period in a twice-daily regimen, with 6 on cycles of 4 weeks duration during the 48-week period.
Study: NCT00684710
Drug: PAZ-417
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00684710
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01375816
Drug: fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01375816
Drug: leucovorin calcium
Normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT05527782
Drug: modified TPF
Approvals — FDA: no, EMA: no, PMDA: no
Description: modified TPF: modified docetaxel-cisplatin-fluorouracil followed by concurrent chemoradiotherapy
Study: NCT01009970
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 750 mg/m2 day 2
Study: NCT01009970
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 50 mg/m2 day 2
Study: NCT00080743
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: One pill po once daily
Study: NCT00003352
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 600 mg/m2, IV, every 3 weeks
Study: NCT03680196
Drug: medication Botulinum A injection.
Approvals — FDA: no, EMA: no, PMDA: no
Description: In cerebral palsy patients, Botulinum toxin within the allowable dose of 16 U / kg per body weight will injected into both adductor longus, adductor magnus muscle at 3 U / kg, adductor brevis, and gracilis muscle at a dose of 1 U / kg.
Study: NCT00918515
Drug: AZD3043
Approvals — FDA: no, EMA: no, PMDA: no
Description: intravenous solution given once as intravenous infusion over 30 minutes
Study: NCT03095456
Drug: Placebo for Spiriva Handihaler®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered as double blind, double dummy via Spiriva HandiHaler®.
Study: NCT01971853
Drug: oral placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen placebo and Acetaminophen placebo will be added to a Demerol-Vistaril regimen
Study: NCT00987116
Drug: Prednisone - Azathioprine
Normalized name: Azathioprine
DrugBank: Azathioprine (DB00993)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Rapid strategy consists of decreasing the prednisone dose if at each monthly consultation the patient fulfils the criteria for improvement or minimal manifestation state, in order to discontinue it before twelve months. The starting dose is 0.75 mg/kg/day.~Classical strategy consists of decreasing the prednisone dose if at each monthly consultation the patient fulfils the criteria for minimal manifestation state, in order to discontinue it before twelve months. The starting dose is 1.5 mg/kg/2days.
Study: NCT04470050
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual Placebo film
Study: NCT03972462
Drug: NPC-12G Gel 0.2%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Period 1
Study: NCT03972462
Drug: Rapamune® 2 mg tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Period 2
Study: NCT02375191
Drug: fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01104545
Drug: MK-3614
Normalized name: vitamin MK 7
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01104545
Drug: Comparator: Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02057640
Drug: MLN9708
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4mg on day 1, 8, 15, 28
Study: NCT00628433
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT02128191
Drug: Oral ibuprofen
Normalized name: ibuprofen Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Initial dose of 10 mg/kg of oral ibuprofen, followed by two doses of 5 mg/kg 24 and 48 hours later
Study: NCT02128191
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Initial dose of normal saline followed by second and third dose 24 and 48 hours later, at equal volume to ibuprofen arm
Study: NCT02209792
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02209792
Drug: BIBR 796 BS, 5 mg
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02209792
Drug: BIBR 796 BS, 20 mg
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04107740
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: BID, 10mg per day, for 24 weeks
Study: NCT00669812
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00669812
Drug: doxorubicin hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00669812
Drug: methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00669812
Drug: prednisolone
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03265197
Drug: Intra-tympanic injection of drugs
Normalized name: purified protein derivative of tuberculin Injectable Solution [Aplisol]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intratympanic injection of combined lidocaine and dexamethasone in treatment of tinnitus
Study: NCT02073279
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be administered subcutaneously (SC) at Weeks 0, 2, and 4, and thereafter once every 4 weeks (Q4W).
Study: NCT00853554
Drug: Dilaudid® tablet 8 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dilaudid® tablet 8 mg, single dose fasting
Study: NCT01964495
Drug: Discontinuation of treatment according to CRP levels
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: The cutoff point is a CRP below 100 mg/L and a reduction to 50% of the initial value.
Study: NCT01964495
Drug: Discontinuation of treatment according to PCT levels
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: The cutoff point is a PCT below 0.25 mcg/L or a reduction to 10% of the initial value.
Study: NCT01964495
Drug: Treatment according to current guidelines
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Often a 7 days course of antibiotics, treatment may be extended if the attending physician deems it necessary.
Study: NCT01006655
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: inhalation twice a day for one month, preceded and followed by adenosine challenge test
Study: NCT01267864
Drug: Ketorolac
Normalized name: Ketorolac
DrugBank: Ketorolac (DB00465)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 30g IVSS
Study: NCT02599753
Drug: 18-FDTBZ
Approvals — FDA: no, EMA: no, PMDA: no
Description: During this study, participants will receive a single i.v. administration of approximately 370MBq (10 mCi) 18F- DTBZ immediately prior to imaging. The dosage of DTBZ is 10 nmole. The effective dose in human body is about 5.6 mSV.~The proposed dose for this study is based on the investigators' phase I study. At the proposed human dose of 10 mCi, the whole body effective dose (ED) will be approximately 680 mrem. The estimated human ED is expected to be comparable to or below the range of other approved brain imaging agents, such as 18F-FDG (Lin 2010).
Study: NCT00395486
Drug: Rosuvastatin
Normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 10mg
Study: NCT01606176
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Each actuation of placebo (100 μl) delivered the excipients only. The maximum permitted dose of study medication was eight actuations in any three hour period and 48 actuations in any 24 hour period.
Study: NCT02443246
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01391481
Drug: Perfluorocarbon
Normalized name: HYDROFLUOROCARBON 227EA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaporized PFC Inhalation 100ml/8h for 5 days
Study: NCT04667598
Drug: Modified Wenxin Decoction
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mainly including make aconite , astragalus ， Cassia twig , dried ginger , red peony root , Chuanxiong , Codonopsis codonopsis , Ophiopogon ophiopogon , Schisandra , Stamen , Asarum , licorice.
Study: NCT01732510
Drug: MK-8226
Normalized name: vitamin MK 7
Approvals — FDA: no, EMA: no, PMDA: no
Description: MK-8226 administered IV at a weight-based dose every 2 weeks for 12 weeks.
Study: NCT01732510
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered IV every 2 weeks for a period of 12 weeks.
Study: NCT00119769
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, 0.7 mg/day injected subcutaneously
Study: NCT00640809
Drug: Celecoxib
Normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 200 mg oral capsule twice daily for 2 weeks
Study: NCT00640809
Drug: Ibuprofen plus Omeprazole
Normalized name: Omeprazole
DrugBank: Omeprazole (DB00338)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ibuprofen 800 mg oral tablet three times daily plus omeprazole 20 mg oral capsule once daily for 2 weeks
Study: NCT00488449
Drug: GSK256073A tablets
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03026231
Drug: Placebo (for PRIM-DJ2727)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thirty eligible subjects with PD will be randomly assigned to receive placebo capsules
Study: NCT02365610
Drug: GWP42006
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02365610
Drug: Placebo Control
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04587830
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Investigational Medicine
Study: NCT04532294
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo to match BGB-DXP593
Study: NCT02561481
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: See under placebo arm description
Study: NCT00002552
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00002552
Drug: leucovorin calcium
Normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00002552
Drug: methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00002552
Drug: therapeutic hydrocortisone
Normalized name: Moisturel Therapeutic
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03909906
Drug: Euphytose®
Approvals — FDA: no, EMA: no, PMDA: no
Description: (50mg Valeriana officinalis L., 40mg Passiflora incarnate L., 10mg Crataegus sp., 10mg Ballota nigra L.)
Study: NCT03909906
Drug: Placebo Oral Tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo comparator
Study: NCT03098537
Drug: enteral nutrition + proton pump inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Critically ill patients receiving any form of enteral nutrition will be included into the study. The patients will be randomized either enteral nutrition only group or enteral nutrition and proton pump inhibitors group. This group will receive enteral nutrition and proton pump inhibitor
Study: NCT00537381
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo matching to intetumumab, as intravenous infusion every week for initial 6 weeks, then every 3 weeks.
Study: NCT02511795
Drug: AZD1775
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZD1775 will be given twice daily (PO BID) over 3 days (6 doses) on Days 1-3 and 8-10 of each 21 day cycle combined with olaparib PO BID on Days 1-14 of each 21 day cycle.~Olaparib will be given orally BID on Days 1-14.
Study: NCT02016716
Drug: Placebo 90 mg/mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered as 2 SC injections with the 1.17 mL crystal zenith resin PFS.
Study: NCT02016716
Drug: Placebo 70 mg/mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered as 3 SC injections with the 1.0 mL glass PFS.
Study: NCT02553551
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: During the period of hospitalization, Intake of gelatinous capsule three times per day via oral route until the day of discharge.~After discharge, no additional capsule was given.
Study: NCT00731770
Drug: Advair 250
Normalized name: Advair 250/50 Metered Dose Inhaler
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 puff bid inhaled
Study: NCT00731770
Drug: Placebo- matched
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 puff bid inhaled
Study: NCT00731770
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo 1 puff bid inhaled
Study: NCT00978419
Drug: Rosuvastatin
Normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Loading dose 40mg by mouth first day, then 20 mg by mouth for up to 27 days
Study: NCT00978419
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered every day for up to 28 days
Study: NCT04548700
Drug: Dose-finding stage: Liposomal mitoxantrone hydrochloride, Cyclophosphamide, Vincristine and Prednisone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug: Liposomal mitoxantrone hydrochloride (12 mg/m2, 15 mg/m2, 18 mg/m2) will be administered by an intravenous infusion on day 1 of each 28-day cycle.~Drug: Cyclophosphamide (750 mg/m2) will be administered by an intravenous infusion on day 1 of each 28-day cycle.~Drug: Vincristine (1.4 mg/m2 with 2 mg as the maximum dose) will be administered by an intravenous injection on day 1 of each 28-day cycle.~Drug: Prednisone (100 mg/d) will be taken orally from day 1 to day 5 of each 28-day cycle.
Study: NCT04548700
Drug: Dose-expansion stage: Liposomal mitoxantrone hydrochloride, Cyclophosphamide, Vincristine and Prednisone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug: Liposomal mitoxantrone hydrochloride (at RP2D) will be administered by an intravenous infusion on day 1 of each 28- or 21-day cycle.~Drug: Cyclophosphamide (750 mg/m2) will be administered by an intravenous infusion on day 1 of each 28- or 21-day cycle.~Drug: Vincristine (1.4 mg/m2 with 2 mg as the maximum dose) will be administered by an intravenous injection on day 1 of each 28- or 21-day cycle.~Drug: Prednisone (100 mg/d) will be taken orally from day 1 to day 5 of each 28- or 21-day.
Study: NCT02142400
Drug: DS-1093
Normalized name: Uretron DS
Approvals — FDA: no, EMA: no, PMDA: no
Description: DS-1093 in capsules with 2.5mg or 25mg per capsule
Study: NCT00811577
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients in the Placebo-only arm were dosed intradermally with placebo (saline) in three trocar sites on Day 9 (plus/minus 2 days) and Day 21 (plus/minus 2 days) after arthroscopic shoulder surgery. In the AZX100-placebo arm, 3 or 10 mg or placebo (saline) was administered intradermally at each of three trocar sites on each patient 9 ± 2 days and 21 ± 2 days after arthroscopic surgery. The three trocar sites (anterior, lateral, and posterior sides of the shoulder) were randomized to receive the same dose of study agent for both dose administrations.
Study: NCT02142400
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: matching placebo capsules to DS-1093 capsules
Study: NCT00811577
Drug: AZX100
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZX100 Drug Product 3 or 10 mg or placebo (saline) was administered intradermally at each of three trocar sites on each patient 9 ± 2 days and 21 ± 2 days after arthroscopic surgery. The three trocar sites (anterior, lateral, and posterior sides of the shoulder) were randomized to receive the same dose of study agent for both dose administrations.
Study: NCT01631669
Drug: Celecoxib
Normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 200 mg Q 12 hours orally
Study: NCT01034982
Drug: AZD9668
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg
Study: NCT01034982
Drug: AZD9668
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg
Study: NCT02147197
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo tablet.
Study: NCT01321255
Drug: Separately drugs, simvastatin, aspirin and ramipril
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin 100 mg once a day Ramipril 2.5; 5; 10 mg once a day Simvastatin 40 mg once a day
Study: NCT01700959
Drug: melatonin
Normalized name: Melatonin
DrugBank: Melatonin (DB01065)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Melatonin 3mg time release will be given. Participants will be instructed to take one 3mg time released tablet by mouth approximately 1-2 hours before initiating sleep onset, preferably at the same time each night.
Study: NCT01700959
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablets to match the melatonin will be comprised of inert substances.
Study: NCT00298441
Drug: chondroitin sulfate-iron colloid
Normalized name: chondroitin sulfate-iron complex
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00255918
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo dosed to match active medication
Study: NCT02897037
Drug: heparin
Normalized name: Heparin
DrugBank: Heparin (DB01109)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: heparin monotherapy
Study: NCT02482428
Drug: Investigational Treatment
Normalized name: INVESTIGATIONAL AGENTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Applied twice daily for up to 12 weeks
Study: NCT00039780
Drug: BNP7787
Approvals — FDA: no, EMA: no, PMDA: no
Description: The treatment regimen administered in this study is a single IV doxe of paclitaxel (80 mg/m2) +/- Herceptin given over 1 hour and either BNP7787 (18.4 g/m2) or placebo given over 45 minutes each week. One treatment cycle = 8 weeks.
Study: NCT00039780
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The treatment regimen administered in this study is a single IV doxe of paclitaxel (80 mg/m2) +/- Herceptin given over 1 hour and either BNP7787 (18.4 g/m2) or placebo given over 45 minutes each week. One treatment cycle = 8 weeks.
Study: NCT00945347
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nasal instillation of placebo matching in appearance with the Miglustat instillation
Study: NCT02407080
Drug: RG7388
Approvals — FDA: no, EMA: no, PMDA: no
Description: RG7388 is supplied as film-coated tablets at dosage strengths of 50 mg, 200 mg, 300mg and 400 mg.
Study: NCT01283776
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 100 mg/kg total dose, infused on day +3 and +3 after allogeneic stem cell transplantation
Study: NCT03347526
Drug: Cosyntropin Injectable Suspension, 1 mg/mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injectable
Study: NCT02479087
Drug: Plasma-derived FVIII/VWF concentrate
Approvals — FDA: no, EMA: no, PMDA: no
Description: The investigational treatment is with lyophilized plasma-derived Factor VIII. The product belongs to the factor VIII concentrates class, containing also VW Factor in an average ratio VW/VIII of \> 1: 4.5.~The product is as a powder and a solvent solution for continuous infusion of Factor VIII. The specific activity of Factor VIII is of approximately 80 IU/mg protein.~The number of units of FVIII administered is expressed in International Units (IU), which are consistent with current WHO standards for products containing Factor VIII. The activity of Factor VIII in plasma is expressed either as a percentage (compared to normal human plasma) or in International Units (compared to the international standard for FVIII in plasma).
Study: NCT01097265
Drug: capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT03462927
Drug: MC2-01 Cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: MC2-01 (calcipotriene/betamethasone dipropionate, w/w 0.005%/0.064%)
Study: NCT03462927
Drug: CAL/BDP combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcipotriene/betamethasone (calcipotriene/ betamethasone dipropionate, w/w 0.005%/0.064%)
Study: NCT01422785
Drug: clindamycin phosphate 1.2%/tretinoin 0.025% gel alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once daily application of the clindamycin phosphate 1.2%/tretinoin 0.025% gel in the evening